Jacqueline Nagl R. Jacobs Chae

200 SCIENTIFIC SESSIONS September 9-12 | F-2045 DS-8587, a New Generation of Broad Spectrum Quinolone: In Vitro Antibacterial Activity against 9 Major Anaerobic Species of Japanese Clinical Isolates

H. Mikamo

1 , Y. Yamagishi 1 , H. Suematsu 1 , H. Sawamura 1 , M. Chiba 2 , R. Okumura 2 , K. Hoshino 2 ; 1 Aichi Med. Univ., Aichi, Japan, 2 Daiichi Sankyo, Co. Ltd., Tokyo, Japan. F-2046 In Vitro Activity of KPI-10 against Clinically Important Gram-Negative Bacteria

J. Deane

1 , A. Simenauer 1 , Y. Ge 2 , P. B. Eckburg 2 , D. Sahm 1 ; 1 Eurofins, Chantilly, VA, 2 Kalidex Pharmaceuticals, Inc., Menlo Park, CA. F-2047 In Vitro Activity of KPI-10 against Clinically Important Gram-Positive Bacteria

J. Deane

1 , A. Simenauer 1 , Y. Ge 2 , P. Eckburg 2 , D. Sahm 1 ; 1 Eurofins, Chan- tilly, VA, 2 Kalidex Pharmaceuticals Inc., Menlo Park, CA. F-2048 Activity of Novel Fluoroquinolone, KPI-10, vs. Multidrug- Resistant Bacteria, Including those with NDM-1 Carbapenemase

D. M. Livermore, M. Warner, S. Mushtaq; Hlth. Protection Agency, Lon- don, United Kingdom.

F-2049 In Vitro Activity and DNA Gyrase Inhibitory Activity of KPI-10, a Novel Fluoroquinolone FQ, against Quinolone- Susceptible QS and Quinolone-Resistant QR

E. coli

D. Kazamori, K. Sugimoto, Diploma, H. Aoi, K. Itoh, Y. Kuramoto, A. Yazaki; Wakunaga Pharmaceutical Co. Ltd., Hiroshima, Japan. F-2050 In Vitro Activity of KPI-10 Tested against a Global Collection of Acinetobacter spp. Including Multidrug-Resistant MDR Strains R. K. Flamm, D. J. Biedenbach, H. S. Sader, M. L. Konrardy, R. N. Jones; JMI Lab., N Liberty, IA. F-2051 KPI-10 In Vitro Activity Tested against Pathogens Common- ly Associated with Community-Acquired Bacterial Pneumonia CABP Infections R. K. Flamm, D. J. Biedenbach, H. S. Sader, M. L. Konrardy, R. N. Jones; JMI Lab., N Liberty, IA. F-2052 KPI-10, a Novel Flouroquinolone FQ Tested against Neisseria gonorrhoeae Including Ciprofloxacin Non-Susceptible CIP-NS and Penicillin Non-Susceptible PEN-NS Strains R. K. Flamm, D. J. Biedenbach, H. S. Sader, M. L. Konrardy, R. N. Jones; JMI Lab., N Liberty, IA. F-2053 In Vitro Activity of KPI-10 Tested against Pathogens Commonly Associated with Urinary Tract infections UTIs R. K. Flamm, D. J. Biedenbach, H. S. Sader, M. L. Konrardy, R. N. Jones; JMI Lab., N Liberty, IA. F-2054 Activity of KPI-10 against Highly Resistant E. coli and

K. pneumoniae from Various Countries

M. A. Habeeb 1 , P. Eckburg 2 , J. Ge 3 , C. G. Giske 4 ; 1 Natl. Inst. for Biotech- nology and Genetic Engineering NIBGE, Faisalabad, Pakistan, 2 Kalidex Pharmaceutical Inc, Menlo Park, CA, 3 Kalidex Pharmaceuticals, Menlo Park, CA, 4 Karolinska Inst., Stockholm, Sweden. F-2055 In Vivo Activity of KPI-10, a Novel Fluoroquinolone FQ, in Mouse Systemic and Local Infection Models Caused by Multidrug- and FQ-Resistant Pathogens H. Amano, H. Aoi, K. Sakata, K. Inokuma, D. Kazamori, K. Itoh, Y. Kuramoto, A. Yazaki; Wakunaga Pharmaceutical Co. Ltd., Akitakata, Japan. F-2056 50 Effective Dose ED50 Determination of KPI-10 for Treating Sepsis in Mice Due to Quinolone-Susceptible QS and Quinolone-Resistant QR Nosocomial Pathogens: Comparison with Ciprofloxacin CIP

C. Jacqueline

1 , M. Davieau 1 , C. Desessard 2 , A. F. Miegeville 1 , Y. Ge 3 , G. Potel 1 , J. Caillon 1 ; 1 UPRES EA 3826, Nantes, France, 2 Atlangram, Nantes, France, 3 Kalidex Pharmaceuticals Inc, Menlo Park, CA. Late-breaker presentations are listed behind the Late-breaker tab of the Final Program. ------------------------------------------------------------------------ 249 F Poster Session Targeting Gram-Negative Pathogens Wednesday, 9:15 a.m.–11:15 a.m. . . . . . . . . . . . . . . . . Halls A-C Presentations: F-2057 FimH Antagonists: A Selective and Highly Effective Novel Therapeutic Approach for the Treatment of Urinary Tract Infection B. Ernst, D. Abgottspon, M. Scharenberg, X. Jiang, O. Schwardt; Inst. of Molecular Pharmacy, Basel, Switzerland. F-2058 N-Chlorotaurine, a Long-Lived Endogenous Oxidant, Inac- tivates Shiga Toxin 2 of Enterohemorrhagic Escherichia coli

M. Nagl

1 , C. Eitzinger 1 , S. Ehrlenbach 1 , H. Lindner 1 , L. Kremser 1 , W. Gottardi 1 , D. Orth 1 , D. Debabov 2 , M. Anderson 2 ; 1 Innsbruck Med. Univ., Innsbruck, Austria, 2 Novabay, Emeryville, CA. F-2059 Activity of Novel Pyrrolocytosine Agents against Multidrug and Carbapenem Resistant Klebsiella pneumoniae

M. R. Jacobs

1 , S. Bajaksouzian 1 , A. R. Windau 1 , A. N. Foster 1 , K. M. Hujer 2 , R. A. Bonomo 2 ; 1 CWRUUniv. Hosp, Cleveland, OH, 2 CWRU,VAMC, Cleveland, OH. F-2060 Antimicrobial Activity and Synergistic Effect of Synthetic Peptides against Antibiotic Resistant Pseudomonas aeruginosa from Gallbladder Bile of Acute Cholecystitis Patients

J. Chae

1 , B. Son 2 , Y. Park 3 , W. Choe 1 , S. Ahn 2 , S. Kim 2 , Y. Jo 2 , Y. Park 2 ; 1 Lab. Med., Eulji Univ. Coll. of Med., Eulji-Gen. Hosp., Seoul, Korea, Republic of, 2 Internal Med., Eulji Univ. Coll. of Med., Eulji-Gen. Hosp., Seoul, Korea, Republic of, 3 Biotechnology and Res. Ctr. for Proteineous Materials RCPM, Chosun Univ., Kwangju, Korea, Republic of. F-2061 Rational Design of Engineered Antimicrobial Peptides Consisting Exclusively of Arginine and Tryptophan

B. Deslouches, J. D. Steckbeck, J. K. Craigo, R. C. Montelaro; Univ. of Pittsburgh, Pittsburgh, PA.